What Is CIDP (Chronic Inflammatory Demyelinating Polyneuropathy)? Symptoms, Causes, Diagnosis & Treatment

Oct 15

13 min read

Updated: 3 days ago

Medically reviewed by Dr. Baraa Alnahhal, MD · Last reviewed: October 2026

Quick Answer: What is CIDP?

CIDP is a rare neurological condition in which the immune system attacks the myelin sheath around peripheral nerves [3] [5]. Its hallmark is muscle weakness that worsens over at least eight weeks, usually on both sides of the body [3] [5]. Corticosteroids, plasma exchange and IVIG are first-line treatments [1] [8], and about two-thirds of people respond to initial treatment [2], though relapses are common.

Key takeaways

Takeaway	What it means for you
CIDP is autoimmune	The immune system attacks the nerves' protective myelin coating [3].
It's the "long-term" version of Guillain-Barré	Symptoms worsen over at least eight weeks, unlike GBS which usually peaks in 2–3 weeks.
Weakness is symmetric	Hips, thighs, shoulders, arms, hands and feet are typically affected equally on both sides [5].
Diagnosis takes several tests	Nerve tests, spinal tap, MRI and blood work all play a role.
Three first-line treatments exist	Corticosteroids, plasma exchange and IVIG calm the immune attack [1] [5].
Outlook is generally good	About two-thirds respond to initial treatment [2]; it's not fatal and doesn't shorten life expectancy.

What the research says

CIDP is rare, and published estimates vary widely. A meta-analysis of 11 studies pooled a crude incidence of 0.33 per 100,000 person-years (95% CI 0.21–0.53) and a prevalence of 2.81 per 100,000 (95% CI 1.58–4.39). The authors found large differences between studies that were partly explained by the use of different diagnostic criteria, which is why quoted figures differ from source to source (Broers et al., Neuroepidemiology, 2019 [6]).
IVIG outperformed placebo in the largest early trial. In the ICE trial of 117 patients with CIDP, 54% (32 of 59) of those given IVIG had a lasting improvement in disability through week 24 versus 21% (12 of 58) given placebo (treatment difference 33.5%, 95% CI 15.4–51.7; p = 0.0002). Serious adverse events were reported in 0.8% of IVIG infusions and 1.9% of placebo infusions, and the most common side effects were headache, fever and high blood pressure (Hughes et al., Lancet Neurol, 2008 [7]).
Current guidelines put IVIG or corticosteroids first, with plasma exchange as the next step. The European Academy of Neurology/Peripheral Nerve Society guideline strongly recommends IVIG or corticosteroids as initial treatment for typical CIDP and its variants, and plasma exchange if those are ineffective. For long-term maintenance it recommends IVIG, subcutaneous immunoglobulin or corticosteroids, and it advises considering combination treatment or an added immunosuppressant if the needed maintenance dose is high (Van den Bergh et al., Eur J Neurol, 2021 [8]).

What Is CIDP?

CIDP (chronic inflammatory demyelinating polyneuropathy) is a rare neurological condition that causes worsening — progressive — muscle weakness, numbness and other symptoms [5]. Breaking the name apart explains a lot about the disease:

Word in the name	What it means
Chronic	Long-term. CIDP slowly develops over at least eight weeks and can improve, then relapse, over months or years.
Inflammatory	Researchers believe CIDP is an autoimmune attack that causes inflammation damaging the peripheral nerves [3] [5] — the nerves outside the brain and spinal cord.
Demyelinating	The inflammation targets the myelin sheath, the protective sleeve wrapped around each nerve cell [3] [5]. Demyelination is the destruction of that sheath.
Polyneuropathy	Malfunction of many peripheral nerves throughout the body ("poly" means many). Neuropathy is the umbrella term for any damage to peripheral nerves.

CIDP vs. Guillain-Barré Syndrome

CIDP is closely related to Guillain-Barré syndrome (GBS), and healthcare providers consider CIDP to be the long-term form of GBS [4]. Both are autoimmune conditions in which the immune system attacks the peripheral nerves. The key difference is timing. The most severe stage of GBS usually comes around two to three weeks after symptoms start, and most people begin improving after that point. CIDP lasts longer — symptoms worsen over at least eight weeks.

How Common Is CIDP?

Researchers estimate a prevalence of 0.8 to 8.9 per 100,000 people [2]. That range is wide because CIDP affects people in many different ways and is difficult to diagnose. CIDP can affect anyone at any age [4] [5].

CIDP Symptoms

The most common symptom is muscle weakness that gets worse over at least eight weeks. The weakness typically affects both sides of the body equally, in the arms and legs: the hips and thighs, shoulders and upper arms, hands and feet [5].

Symptom	What you might notice
Muscle weakness	Worsens over at least eight weeks, usually equal on both sides; hips, thighs, shoulders, upper arms, hands and feet.
Tingling or numbness	Prickliness or numbness in fingers and toes (paresthesia) [5].
Muscle atrophy	Loss of muscle mass in the affected muscles [5].
Balance issues	Difficulties with balance and coordination, often described as clumsiness [5].
Loss of mobility	Everyday movement becomes harder as weakness progresses.
Lost reflexes	Loss or weakening of deep tendon (muscle stretch) reflexes [2] [4].
Neuropathic pain	Nerve-related pain in the affected areas [5].
Difficulty swallowing (rare)	Dysphagia and weakness above the neck, in rare cases.
Double vision (rare)	Vision issues in rare cases.

Nine-tile icon grid showing CIDP symptoms: leg weakness, arm weakness, tingling in the hands, numbness in the foot, nerve pain, unsteady walking, a reflex hammer test, nerve signal disruption in the leg, and muscle wasting in the arm – rinnit.com — Common CIDP symptoms, including weakness, tingling, numbness, balance problems, lost reflexes, nerve pain and muscle wasting.

Symptoms may change in severity over time. They can come on slowly or rapidly, and sometimes come and go over months or years. If you develop symptoms like these, see a healthcare provider as soon as possible — early diagnosis and treatment are key to recovery.

Variants of CIDP

Certain variants (types) of CIDP produce different symptom patterns. Typical CIDP is the most common form, with symmetric muscle weakness and sensory symptoms on both sides of the body.

Variant	Symptom pattern
Typical CIDP (most common)	Symmetric muscle weakness plus sensory symptoms (numbness, tingling).
Multifocal motor neuropathy	A separate condition that can look similar: uneven muscle weakness without numbness. It is not a CIDP variant and is treated differently, mainly with IVIG.
Lewis-Sumner syndrome	Asymmetric muscle weakness plus sensory symptoms [5] [8].
Pure sensory CIDP	Numbness, pain, balance issues and an abnormal walking pattern — no muscle weakness.
Pure motor CIDP	Symmetric muscle weakness and loss of reflexes — no sensory symptoms.

Researchers are currently studying other variants of CIDP.

What Causes CIDP?

Researchers believe CIDP happens because of a problem with the immune system. For reasons that remain unknown, the immune system sees myelin as dangerous and attacks it in an autoimmune reaction [3] [5]. Myelin is the protective layer wrapped around nerve cells. It coats the nerve axon — the long, wire-like part of a nerve cell — and allows electrical impulses to travel efficiently along the nerve [3]. When myelin is damaged or removed, those impulses slow down or stop, and the messages may never reach their destination. That's what causes the symptoms of CIDP.

How Is CIDP Diagnosed?

CIDP can be difficult to diagnose, especially since different variants produce different symptoms. A healthcare provider starts by assessing symptoms and medical history, then performs physical and neurological exams. From there, several tests help confirm the diagnosis or rule out other causes:

Test	What it does
EMG and nerve conduction tests	Evaluate the health of skeletal muscles and the nerves that control them. They look for demyelination changes like slowing and blocks [5], which distinguish CIDP from the more common types of polyneuropathy.
Spinal tap (lumbar puncture)	A needle in the lower back collects cerebrospinal fluid (CSF) for lab analysis [3]. In about 85% to 90% of CIDP cases, white blood cells are only mildly raised (fewer than 10 cells/mm³) and CSF protein is elevated [2].
MRI of the lumbar spine	If nerve roots in the lower back pick up contrast dye, it supports the CIDP diagnosis.
Blood tests	Rule out other causes of neuropathy like diabetes, vitamin deficiencies, thyroid disease, Lyme disease, HIV/AIDS and lymphoma. Antibodies linked to CIDP may also be checked.
Nerve biopsy	In rare cases, a small nerve sample is examined for evidence of demyelination [3].

How is CIDP treated?

There are three first-line treatments for CIDP:

Treatment	How it works
Corticosteroids	Prescription steroids like prednisone reduce inflammation. Many people improve with corticosteroids alone, though serious side effects limit how long they can be taken. Immunosuppressants are sometimes prescribed alongside them [3].
Plasma exchange (plasmapheresis)	A machine separates plasma from the blood, filters out the antibodies attacking the nerves, and returns the cleaned plasma and blood to the body. Effective for a few weeks; intermittent treatments may continue over months or years.
IVIG (intravenous immunoglobulin)	IV injections of immunoglobulins — proteins the immune system naturally makes — collected from thousands of healthy donors. They lessen the immune attack on nerves. Very high initial doses are common, followed by intermittent treatments over months or years.

Four-panel strip showing CIDP treatment options: a corticosteroid pill bottle, a plasma exchange machine, an IVIG infusion bag, and a physical therapist helping a patient walk – rinnit.com — CIDP treatment options: corticosteroids, plasma exchange, IVIG therapy and physical rehabilitation.

Researchers are also studying other forms of treatment, and clinical trials may be an option — talk with your provider about eligibility.

What Is the Outlook for CIDP?

The long-term prognosis depends on several factors: your age when CIDP began, how the condition develops and which variant type you have, how quickly you receive a diagnosis and treatment, and how your body initially responds to treatment. The overall numbers are encouraging: about two-thirds of people with CIDP respond to initial treatment, though there is a relapse rate of about 45% with IVIG, 50% with corticosteroids and 67% with plasma exchange [2]. The long-term prognosis is good for people diagnosed at a younger age. The important caveat is that without treatment, CIDP can cause permanent nerve damage that results in disability. CIDP is not a fatal condition, and people with it typically have the same life expectancy as someone without it.

Can CIDP Be Prevented?

Because researchers don't know what triggers CIDP, there's no known way to prevent developing it.

Living With CIDP

If you've been diagnosed with CIDP, you'll need to see your healthcare provider regularly to monitor symptoms and receive treatment. CIDP symptoms can come and go over months or years, which is why treatment is often ongoing [3]. Go to the ER or call emergency services if you have trouble breathing. In rare cases, CIDP can affect the muscles you need to breathe — that's an emergency that needs immediate attention. It can feel scary to feel like you've lost control of your body, but the good news is that CIDP symptoms are treatable — especially when treatment starts right away. Your healthcare team will support you every step of the way.

Conclusion

CIDP is a rare autoimmune disease where the immune system mistakenly strips the protective myelin from peripheral nerves, disrupting the messages that keep muscles strong and sensations normal. Its signature is muscle weakness that worsens over at least eight weeks, usually equally on both sides of the body. Diagnosing it takes a combination of nerve tests, spinal fluid analysis and sometimes imaging, and treating it relies on three proven first-line therapies — corticosteroids, plasma exchange and IVIG. About two-thirds of people respond to initial treatment, and while relapses are common, ongoing care keeps most people moving forward with a normal life expectancy. If you need clear visuals to explain autoimmune and nerve conditions to patients, students or loved ones, Rinnit's infographic templates turn complicated medical concepts into simple, shareable graphics.

Frequently Asked Questions

What is CIDP in simple terms?

CIDP is a rare disease where the immune system attacks the protective coating around the body's peripheral nerves, causing muscle weakness and numbness that worsen over at least eight weeks.

What does CIDP stand for?

Chronic inflammatory demyelinating polyneuropathy — chronic (long-term), inflammatory (immune-related inflammation), demyelinating (myelin damage), polyneuropathy (many nerves affected).

Is CIDP an autoimmune disease?

Yes. CIDP is an autoimmune condition in which the immune system mistakenly attacks the myelin sheath around peripheral nerves.

Is CIDP a neurological disease?

Yes. CIDP is a rare neurological condition affecting the peripheral nerves outside the brain and spinal cord.

Is CIDP a form of neuropathy?

Yes. "Polyneuropathy" means many peripheral nerves are malfunctioning, and neuropathy is the umbrella term for peripheral nerve damage.

What is the myelin sheath?

The myelin sheath is the protective sleeve wrapped around each nerve cell that lets electrical impulses travel efficiently along the nerve.

What happens when myelin is damaged?

Electrical impulses slow down or stop, and nerve messages may never reach their destination, causing weakness and abnormal sensations.

What is demyelination?

Demyelination is the destruction of the myelin sheath around nerve cells.

What are peripheral nerves?

Peripheral nerves are the nerves outside the brain and spinal cord that carry messages between the central nervous system and the rest of the body.

Is CIDP the same as Guillain-Barré syndrome?

No, but they're closely related. Providers consider CIDP the long-term form of GBS — GBS usually peaks in 2–3 weeks and then improves, while CIDP worsens over at least eight weeks.

How is CIDP different from GBS?

GBS reaches its most severe stage around two to three weeks after symptoms start, then most people improve. CIDP symptoms worsen over at least eight weeks and last much longer.

How rare is CIDP?

Researchers estimate a prevalence of 0.8 to 8.9 per 100,000 people.

Who gets CIDP?

CIDP can affect anyone at any age.

What is the main symptom of CIDP?

Muscle weakness that worsens over at least eight weeks, usually equally on both sides of the body.

What muscles does CIDP affect?

Typically the hips and thighs, shoulders and upper arms, hands and feet — usually equally on both sides.

Does CIDP cause numbness?

Yes. Tingling, prickliness or numbness in fingers and toes (paresthesia) is a common symptom.

Can CIDP cause pain?

Yes. Neuropathic (nerve-related) pain is one of the symptoms.

Does CIDP affect balance?

Yes. Balance and coordination difficulties, often described as clumsiness, are common.

Can CIDP cause muscle loss?

Yes. Muscle atrophy — loss of muscle mass in the affected muscles — can occur.

Does CIDP affect reflexes?

Yes. Loss or weakening of deep tendon (muscle stretch) reflexes is a recognized symptom.

Can CIDP affect swallowing?

In rare cases, yes — difficulty swallowing (dysphagia) and weakness above the neck can occur.

Can CIDP cause double vision?

In rare cases, yes.

Do CIDP symptoms come and go?

Yes. Symptoms can change in severity, come on slowly or rapidly, and sometimes come and go over months or years.

What are the variants of CIDP?

Typical CIDP (symmetric weakness plus sensory symptoms), Lewis-Sumner syndrome (asymmetric weakness plus sensory symptoms), pure sensory CIDP (no weakness) and pure motor CIDP (no sensory symptoms).

What is pure sensory CIDP?

A variant with numbness, pain, balance issues and an abnormal walking pattern but no muscle weakness.

What is pure motor CIDP?

A variant with symmetric muscle weakness and loss of reflexes but no sensory symptoms.

What is Lewis-Sumner syndrome?

An atypical CIDP variant with asymmetric muscle weakness plus sensory symptoms.

What is multifocal motor neuropathy?

A separate nerve condition, not a CIDP variant, that causes uneven muscle weakness without numbness. It is usually treated with IVIG, because steroids and plasma exchange may not help.

What causes CIDP?

For unknown reasons, the immune system sees myelin as dangerous and attacks it in an autoimmune reaction.

Can CIDP be inherited?

CIDP is caused by an autoimmune reaction, not directly inherited, though researchers are still studying why it develops in some people.

Can CIDP be triggered?

Researchers don't know what triggers CIDP.

How is CIDP diagnosed?

Through symptom assessment, medical history, physical and neurological exams, plus tests like electromyography (EMG), nerve conduction studies, spinal tap, MRI and blood work.

What does an EMG show in CIDP?

EMG and nerve conduction tests look for demyelination changes — like slowing and blocks — in the nerves, which distinguishes CIDP from more common polyneuropathies.

What does a spinal tap show in CIDP?

In about 85% to 90% of CIDP cases, cerebrospinal fluid has an elevated protein level and only mildly raised white blood cells (fewer than 10 cells/mm³).

Can MRI detect CIDP?

An MRI of the lumbar spine can support the diagnosis if nerve roots in the lower back pick up contrast dye.

What blood tests are used for CIDP?

Blood tests rule out other neuropathy causes like diabetes, vitamin deficiencies, thyroid disease, Lyme disease, HIV/AIDS and lymphoma, and may check antibodies linked to CIDP.

Is a nerve biopsy needed for CIDP?

Only in rare cases, to look for evidence of demyelination.

Is CIDP curable?

CIDP is treatable but chronic — it can improve and relapse over months or years, often requiring ongoing treatment.

What are the first-line treatments for CIDP?

Corticosteroids, plasma exchange (plasmapheresis) and IVIG (intravenous immunoglobulin).

Do corticosteroids work for CIDP?

Yes. Many people improve with corticosteroids alone, though serious side effects limit how long they can be taken; immunosuppressants are sometimes added.

What is plasma exchange for CIDP?

A machine separates plasma from blood, filters out the antibodies attacking the nerves, and returns the cleaned blood to the body.

How long does plasma exchange work for CIDP?

It's typically effective for a few weeks, so intermittent treatments may continue over months or years.

What is IVIG?

Intravenous immunoglobulin — IV injections of immune proteins collected from thousands of healthy donors that lessen the immune attack on nerves.

How is IVIG given for CIDP?

Very high doses initially, then continued intermittent treatments over months or years as needed.

Are there clinical trials for CIDP?

Yes. Researchers are studying other treatments, and clinical trial participation may be an option — ask your provider.

Does CIDP treatment work?

About two-thirds of people with CIDP respond to initial treatment.

Does CIDP come back after treatment?

It can. Relapse rates are about 45% with IVIG, 50% with corticosteroids and 67% with plasma exchange, which is why ongoing, on-and-off treatment over months or years is common.

Is CIDP permanent?

Untreated CIDP can cause permanent nerve damage leading to disability, but early treatment is key to recovery and preventing lasting damage.

Is CIDP fatal?

No. CIDP isn't a fatal condition.

Does CIDP affect life expectancy?

People with CIDP typically have the same life expectancy as someone without the condition.

What factors affect the CIDP prognosis?

Age at onset, how the condition develops and the variant type, how quickly diagnosis and treatment happen, and initial response to treatment.

Is the outlook better for younger people with CIDP?

Yes. Overall long-term prognosis is good for people diagnosed at a younger age.

Can CIDP be prevented?

No — since researchers don't know what triggers CIDP, there's no known way to prevent it.

How often should I see my doctor with CIDP?

Regularly. Monitoring symptoms and ongoing treatment over months or years are essential, since symptoms can come and go.

When should I go to the ER for CIDP?

If you have trouble breathing — in rare cases CIDP affects the breathing muscles, and that's a medical emergency.

Why is early treatment important for CIDP?

Early diagnosis and treatment are key to recovery and help prevent permanent nerve damage and disability.

Can you live a normal life with CIDP?

Many people do. About two-thirds respond to initial treatment, the condition isn't fatal, and life expectancy is typically normal.

References

GBS|CIDP Foundation International. Intro to Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). GBS|CIDP Foundation International. Accessed October 30, 2026. https://www.gbs-cidp.org/cidp/
Gogia B, Rocha Cabrero F, Khan Suheb MZ, et al. Chronic Inflammatory Demyelinating Polyradiculoneuropathy. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Updated March 4, 2024. PMID 33085396. https://www.ncbi.nlm.nih.gov/books/NBK563249/
Feldman AM. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Merck Manual Consumer Version. Full review May 2026; last updated Oct 2026. https://www.merckmanuals.com/home/brain,-spinal-cord,-and-nerve-disorders/peripheral-nerve-and-related-disorders/chronic-inflammatory-demyelinating-polyneuropathy-cidp
National Institute of Neurological Disorders and Stroke. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). NINDS. Last reviewed November 28, 2023. Archived January 9, 2024. https://web.archive.org/web/20240109051535/https://www.ninds.nih.gov/health-information/disorders/chronic-inflammatory-demyelinating-polyneuropathy-cidp
National Organization for Rare Disorders. Chronic Inflammatory Demyelinating Polyneuropathy. NORD Rare Disease Database. Last updated October 1, 2024. https://rarediseases.org/rare-diseases/chronic-inflammatory-demyelinating-polyneuropathy/
Broers MC, Bunschoten C, Nieboer D, et al. Incidence and Prevalence of Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Systematic Review and Meta-Analysis. Neuroepidemiology. 2019;52(3-4):161-172. PMID: 30669140. https://doi.org/10.1159/000494291
Hughes RAC, Donofrio P, Bril V, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol. 2008;7(2):136-144. PMID: 18178525. https://doi.org/10.1016/S1474-4422(07)70329-0
Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second revision. Eur J Neurol. 2021;28(11):3556-3583. PMID: 34327760. https://doi.org/10.1111/ene.14959

Medical disclaimer

This content is for general informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for diagnosis and treatment of any medical condition.